Pauline Terebuh

Dr. Pauline Terebuh

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
VOVeronica R. Olaker
Veronica R. Olaker
SFSarah Fry
Sarah Fry
PTPauline Terebuh
Pauline Terebuh
PDPamela B. Davis
Pamela B. Davis
DTDaniel J. Tisch
Daniel J. Tisch
DKDavid . Kaelber
David . Kaelber
Electronic health records (EHRs), though they are maintained and utilized for clinical and billing purposes, may provide a wealth of information for research. Currently, sources are available that offer insight into the health histories of well over a quarter of a billion people. Their use, however, is fraught with hazards, including introduction or reinforcement of biases, clarity of disease definitions, protection of patient privacy, definitions of covariates or confounders, accuracy of medication usage compared with prescriptions, the need to introduce other data sources such as vaccination or death records and the ensuing potential for inaccuracy, duplicative records, and understanding and interpreting the outcomes of data queries. On the other hand, the possibility of study of rare disorders or the ability to link apparently disparate events are extremely valuable. Strategies for avoiding the worst pitfalls and hewing to conservative interpretations are essential. This article summarizes many of the approaches that have been used to avoid the most common pitfalls and extract the maximum information from aggregated, standardized, and de‐identified EHR data. This article describes 26 topics broken into three major areas: (1) 14 topics related to design issues for observational study using EHR data, (2) 7 topics related to analysis issues when analyzing EHR data, and (3) 5 topics related to reporting studies using EHR data.

1 October 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
MMMargaret G. Miller
Margaret G. Miller
PTPauline Terebuh
Pauline Terebuh
DKDavid C. Kaelber
David C. Kaelber
RXRong Xu
Rong Xu
PDPamela B. Davis
Pamela B. Davis
Infection with SARS-CoV-2 is associated with a wide range of subsequent chronic illness in patients, including diabetes.1,2 Among adults, a meta-analysis considering data from December 2019 through October 20223 found an overall 66% higher risk of new-onset diabetes after SARS-CoV-2 infection; a second meta-analysis4 found that 12 of 14 studies found a significantly increased risk, ranging from 11% to 276%, for new-onset diabetes after SARS-CoV-2 infection. Several studies4,5 indicate that this risk is greater in male patients and in those with more severe SARS-CoV-2 infection.

1 October 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
MMMargaret G. Miller
Margaret G. Miller
PTPauline Terebuh
Pauline Terebuh
DKDavid C. Kaelber
David C. Kaelber
RXRong Xu
Rong Xu
PDPamela B. Davis
Pamela B. Davis
The first glucagon-like peptide-1 receptor agonists (GLP-1RAs) to be approved for preadolescent and adolescent populations was liraglutide in 2019, which treated type 2 diabetes (T2D). Exenatide and semaglutide approval for preadolescent and adolescent T2D and obesity soon followed.1 A recent study reported a 600% increase in patients aged 12 to 25 years who were prescribed GLP-1RAs between 2020 and 2023.2

15 October 2020 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PDF file
PTPauline Terebuh
Pauline Terebuh
AEAmina J. Egwiekhor
Amina J. Egwiekhor
HGHeidi L. Gullett
Heidi L. Gullett
AFAdeola O. Fakolade
Adeola O. Fakolade
JMJill E. Miracle
Jill E. Miracle
TATerrence Allan
Terrence Allan
Background: Clusters of COVID‐19 cases amplify the pandemic and are critical targets for intervention, but comprehensive cluster‐level data are not collected systematically by federal or most state public health entities. This analysis characterizes COVID‐19 clusters among vulnerable populations housed in congregate living settings across an entire community and describes early mitigation efforts.Methods: The Cuyahoga County Board of Health identified and interviewed COVID‐19 cases and exposed contacts, assessing possible connections to congregate living facilities within its jurisdiction from March 7, 2020, to May 15, 2020, during the first phase of the pandemic, while state of Ohio stay‐at‐home orders were in effect. A multi‐disciplinary team‐based response network was mobilized to support active case finding and develop facility‐focused containment strategies.Results: We identified a cascade of 45 COVID‐19 clusters across community facilities (corrections, nursing, assisted living, intermediate care, extended treatment, shelters, group homes). Attack rates were highest within small facilities (P < .01) and large facilities requiring extensive support to implement effective containment measures. For 25 clusters, we identified an index case who frequently (88%) was a healthcare worker. Engagement of clinical, community, and government partners through public health coordination efforts created opportunities to rapidly develop and coordinate effective response strategies to support the facilities facing the dawning impact of the pandemic.Conclusions: Active cluster investigations can uncover the dynamics of community transmission affecting both residents of congregate settings and their caregivers and help to target efforts toward populations with ongoing challenges in access to detection and control resources.

18 January 2024 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
CWChristina X. Wang
Christina X. Wang
RKRhea Kohli
Rhea Kohli
VOVeronica R. Olaker
Veronica R. Olaker
PTPauline Terebuh
Pauline Terebuh
RXRong Xu
Rong Xu
PDPamela B. Davis
Pamela B. Davis
COVID-19 is associated with increased risks for mood or anxiety disorders, but it remains uncertain how the association evolves over time or which patient groups are most affected. We conducted a retrospective cohort study using a nationwide database of electronic health records to determine the risk of depressive or anxiety disorder diagnoses after SARS-CoV-2 infection by 3-month blocks from January 2020 to April 2022. The study population comprised 822,756 patients (51.8% female; mean age 42.8 years) with COVID-19 and 2,034,353 patients with other respiratory tract infections (RTIs) (53.5% female, mean age 30.6 years). First time diagnoses of depressive or anxiety disorders 14 days to 3 months after infection, as well as new or new plus recurrent prescriptions of antidepressants or anxiolytics, were compared between propensity score matched cohorts using Kaplan-Meier survival analysis, including hazard ratio (HR) and 95% confidence interval (CI). Risk of a new diagnosis or prescription was also stratified by age, sex, and race to better characterize which groups were most affected. In the first three months of the pandemic, patients infected with SARS-CoV-2 had significantly increased risk of depression or anxiety disorder diagnosis (HR 1.65 [95% CI, 1.30-2.08]). October 2021 to January 2022 (HR, 1.12 [95% CI, 1.06–1.18]) and January to April 2022 (HR, 1.08 [95% CI, 1.01–1.14]). Similar temporal patterns were observed for antidepressant and anxiolytic prescriptions, when the control group was patients with bone fracture, when anxiety and depressive disorders were considered separately, when recurrent depressive disorder was tested, and when the test period was extended to 6 months. COVID-19 patients ≥65 years old demonstrated greatest absolute risk at the start of the pandemic (6.8%), which remained consistently higher throughout the study period (HR, 1.20 [95% CI, 1.13–1.27]), and overall, women with COVID-19 had greater risk than men (HR 1.35 [95% CI 1.30–1.40]).

25 January 2024 in Family Medicine and Community Health
Verified
Journal Article
Open access
PDF file
PTPauline Terebuh
Pauline Terebuh
VOVeronica R Olaker
Veronica R Olaker
EKEllen K Kendall
Ellen K Kendall
DKDavid C Kaelber
David C Kaelber
RXRong Xu
Rong Xu
PDPamela B Davis
Pamela B Davis
Objective Beginning in October 2021 in the USA and elsewhere, cases of severe paediatric hepatitis of unknown aetiology were identified in young children. While the adenovirus and adenovirus-associated virus have emerged as leading aetiological suspects, we attempted to investigate a potential role for SARS-CoV-2 in the development of subsequent liver abnormalities. Design We conducted a study using retrospective cohorts of deidentified, aggregated data from the electronic health records of over 100 million patients contributed by US healthcare organisations. Results Compared with propensity score matched children with other respiratory infections, children aged 1–10 years with COVID-19 had a higher risk of elevated transaminases (HR (95% CI) 2.16 (1.74 to 2.69)) or total bilirubin (HR (95% CI) 3.02 (1.91 to 4.78)), or new diagnoses of liver diseases (HR (95% CI) 1.67 (1.21 to 2.30)) from 1 to 6 months after infection. Patients with pre-existing liver abnormalities, liver abnormalities surrounding acute infection, younger age (1–4 years) or illness requiring hospitalisation all had similarly elevated risk. Children who developed liver abnormalities following COVID-19 had more pre-existing conditions than those who developed abnormalities following other infections. Conclusion These results indicate that SARS-CoV-2 may prime the patient for subsequent development of liver infections or non-infectious liver diseases. While rare (~1 in 1000), SARS-CoV-2 is a risk for subsequent abnormalities in liver function or the diagnosis of diseases of the liver.